<DOC>
	<DOCNO>NCT03027193</DOCNO>
	<brief_summary>A phase I dose escalation study assess safety immunogenicity candidate vaccine ChAdOx2 HAV healthy volunteer . Volunteers recruit vaccinated Oxford , England . All vaccination administer intramuscularly . Three different dos test ( 5x10^9 vp , 2.5x10^10 vp 5x10^10vp ) . The total duration study 52 week day enrolment volunteer .</brief_summary>
	<brief_title>A Study Determine Safety Immunogenicity Candidate MAP Vaccine ChAdOx2 HAV Healthy Adult Volunteers</brief_title>
	<detailed_description>This phase I , open label , 3+3 dose escalation trial ass safety immunogenicity ChAdOx2 HAV vaccine Mycobacterium avium subspecies paratuberculosis ( MAP ) healthy volunteer There 3 study group total 12-18 volunteer . ChAdOx2 HAV administer intramuscularly single vaccination 3 different dos : 5x10^9 vp ( group 1 ) , 2.5x10^10 ( group 2 ) 5x10^10 vp ( group 3 ) Vaccination group sequential Group 1 Group 3 interim safety review prior dose escalation Volunteers recruit undergo screen visit , vaccination clinic visit post-vaccination trial site . Blood sample safety immunology purpose perform visit time point indicate schedule attendance . Safety assess frequency , incidence nature adverse event serious adverse event arise study .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy adult age 18 50 year 2 . Able willing ( Investigator 's opinion ) comply study requirement 3 . Willing allow investigator discuss volunteer 's medical history General Practitioner 4 . For female , willingness practice continuous effective contraception ( see ) study negative pregnancy test day ( ) screen vaccination 5 . Agreement refrain blood donation course study 6 . Provide write informed consent 1 . Participation another research study involve receipt investigational product 30 day precede enrolment , plan use study period 2 . Prior receipt investigational vaccine likely impact interpretation trial data . 3 . Prior receipt adenoviral vectored vaccine last 12 month 4 . Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate 5 . Any confirmed suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) 6 . History allergic disease reaction likely exacerbate component vaccine 7 . Any history hereditary angioedema , acquire angioedema , idiopathic angioedema . 8 . Any history anaphylaxis relation vaccination 9 . Pregnancy , lactation willingness/intention become pregnant study 10 . History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) 11 . History serious psychiatric condition likely affect participation study 12 . Bleeding disorder ( eg . Factor deficiency , coagulopathy platelet disorder ) , prior history significant bleed bruise follow IM injection venepuncture 13 . Any serious chronic illness require hospital specialist supervision 14 . Suspected known current alcohol abuse define alcohol intake great 42 unit every week 15 . Suspected known inject drug abuse 5 year precede enrolment 16 . Seropositive hepatitis C ( antibody HCV ) 17 . Seropositive hepatitis B surface antigen ( HBsAg ) 18 . Any clinically significant abnormal find screen biochemistry haematology blood test urinalysis 19 . Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data 20 . Inability study team contact volunteer 's GP confirm medical history safety participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>